BACKGROUND: There is increasing evidence that subsyndromal manic symptoms occur frequently during bipolar major depressive episodes (MDEs) and may be a subtle form of 'depressive mixed state.' This paper examines the prevalence and clinical characteristics of MDEs with subsyndromal manic symptoms. The specific effects of overt irritability and psychomotor agitation are examined. METHODS: Bipolar (type I or II) patients with an MDE at intake (N=142) were compared based on the presence or absence of concurrent subsyndromal manic symptoms. The groups were further subdivided by the presence of symptoms of overt irritability and/or psychomotor agitation. RESULTS: Subsyndromal manic symptoms during bipolar MDEs were highly prevalent (76.1%), and were associated with significantly increased severity of depression/dysphoria in the intake episode, longer episode duration, and more suicidal ideation and behavior (past, current, and during long-term follow-up). Overt irritability and psychomotor agitation were the most prevalent subsyndromal manic symptoms (co-occurring in 57% and 39% of MDEs, respectively), and accounted for most of the negative effects associated with subsyndromal manic symptoms. LIMITATIONS: The findings need to be confirmed in larger samples, which also examine the relationship to adequate antidepressant and/or mood stabilizing treatment. CONCLUSIONS: The presence of one or more subsyndromal manic symptoms appears to be the modal presentation of bipolar MDEs and a marker for a subtle form of bipolar mixed depressive state. In particular, patients with symptoms of overt irritability and/or psychomotor agitation should be monitored closely to avoid serious clinical outcomes such as longer affective episodes, exacerbation of manic symptoms syndromal mania, and heightened suicidality.
BACKGROUND: There is increasing evidence that subsyndromal manic symptoms occur frequently during bipolar major depressive episodes (MDEs) and may be a subtle form of 'depressive mixed state.' This paper examines the prevalence and clinical characteristics of MDEs with subsyndromal manic symptoms. The specific effects of overt irritability and psychomotor agitation are examined. METHODS: Bipolar (type I or II) patients with an MDE at intake (N=142) were compared based on the presence or absence of concurrent subsyndromal manic symptoms. The groups were further subdivided by the presence of symptoms of overt irritability and/or psychomotor agitation. RESULTS:Subsyndromal manic symptoms during bipolar MDEs were highly prevalent (76.1%), and were associated with significantly increased severity of depression/dysphoria in the intake episode, longer episode duration, and more suicidal ideation and behavior (past, current, and during long-term follow-up). Overt irritability and psychomotor agitation were the most prevalent subsyndromal manic symptoms (co-occurring in 57% and 39% of MDEs, respectively), and accounted for most of the negative effects associated with subsyndromal manic symptoms. LIMITATIONS: The findings need to be confirmed in larger samples, which also examine the relationship to adequate antidepressant and/or mood stabilizing treatment. CONCLUSIONS: The presence of one or more subsyndromal manic symptoms appears to be the modal presentation of bipolar MDEs and a marker for a subtle form of bipolar mixed depressive state. In particular, patients with symptoms of overt irritability and/or psychomotor agitation should be monitored closely to avoid serious clinical outcomes such as longer affective episodes, exacerbation of manic symptoms syndromal mania, and heightened suicidality.
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; William Coryell; Jean Endicott; Jack D Maser; David A Solomon; Andrew C Leon; Martin B Keller Journal: Arch Gen Psychiatry Date: 2003-03
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; Jean Endicott; Jack Maser; David A Solomon; Andrew C Leon; John A Rice; Martin B Keller Journal: Arch Gen Psychiatry Date: 2002-06
Authors: Lewis L Judd; Pamela J Schettler; Hagop S Akiskal; Jack Maser; William Coryell; David Solomon; Jean Endicott; Martin Keller Journal: Int J Neuropsychopharmacol Date: 2003-06 Impact factor: 5.176
Authors: Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; William Coryell; Jack Maser; John A Rice; David A Solomon; Martin B Keller Journal: J Affect Disord Date: 2003-01 Impact factor: 4.839
Authors: Ronny Redlich; Jorge J R Almeida; Dominik Grotegerd; Nils Opel; Harald Kugel; Walter Heindel; Volker Arolt; Mary L Phillips; Udo Dannlowski Journal: JAMA Psychiatry Date: 2014-11 Impact factor: 21.596
Authors: Diego Freitas Tavares; Paulo Suen; Carla Garcia Rodrigues Dos Santos; Doris Hupfeld Moreno; Leandro Da Costa Lane Valiengo; Izio Klein; Lucas Borrione; Pamela Marques Forte; André R Brunoni; Ricardo Alberto Moreno Journal: Neuropsychopharmacology Date: 2021-06-30 Impact factor: 7.853
Authors: Maria Faurholt-Jepsen; Maj Vinberg; Mads Frost; Sune Debel; Ellen Margrethe Christensen; Jakob E Bardram; Lars Vedel Kessing Journal: Int J Methods Psychiatr Res Date: 2016-04-01 Impact factor: 4.035